Protocol for a randomised controlled trial to compare postoperative complications between minimally invasive and open DIStal PAnCreaTectomy (DISPACT-2 trial)

• Published in: BMJ open 2021-02, Vol.11 (2), p.e047867-e047867
• Main Authors: Probst, Pascal, Schuh, Fabian, Dörr-Harim, Colette, Sander, Anja, Bruckner, Thomas, Klose, Christina, Rossion, Inga, Nickel, Felix, Müller-Stich, Beat Peter, Mehrabi, Arianeb, Hackert, Thilo, Büchler, Markus W., Diener, Markus K.
• Format: Article
• Language: English
• Subjects: Abdomen; Abdominal surgery; Fistula; Humans; Hypotheses; Laparoscopy; Metastasis; minimally invasive surgery; Minimally Invasive Surgical Procedures; Morbidity; Mortality; Multicenter Studies as Topic; Pancreatectomy; Pancreatectomy - adverse effects; pancreatic disease; Pancreatic Neoplasms - surgery; pancreatic surgery; Patients; Postoperative Complications - epidemiology; Randomized Controlled Trials as Topic; Recovery (Medical); Robotics; Surgery; Surgical outcomes; Treatment Outcome; Veins & arteries
• ISSN: 2044-6055; 2044-6055
• DOI: 10.1136/bmjopen-2020-047867

IntroductionIn recent years, minimally invasive distal pancreatectomy (MIDP) has been used with increasing frequency to accelerate patient recovery. Distal pancreatectomy has an overall morbidity rate of 30%–40%. The known advantages of minimally invasive techniques must be rigorously compared with those of open surgery before they can be completely implemented into clinical practice.Methods and analysisDISPACT-2 is a multicentre randomised controlled trial comparing minimally invasive (conventional laparoscopic or robotic assisted) with open distal pancreatic resection in patients undergoing elective surgery for benign as well as malign diseases of the pancreatic body and tail. After screening for eligibility and obtaining informed consent, a total of 294 adult patients will be preoperatively randomised in a 1:1 ratio. The primary hypothesis is that MIDP is non-inferior to open distal pancreatectomy in terms of postoperative mortality and morbidity expressed as the Comprehensive Complication Index (CCI) within 3 months after index operation, with a non-inferiority margin of 7.5 CCI points. Secondary endpoints include pancreas-specific complications, oncological safety and patient reported outcomes. Follow-up for each individual patient will be 2 years.Ethics and disseminationThe DISPACT-2 trial has been approved by the Ethics Committee of the medical faculty of Heidelberg University (S-693/2017). Results of the primary endpoint will be available in 2024 and will be published at national and international meetings. Full results will be made available in an open access, peer-reviewed journal. The website www.dispact.de contains up-to-date information regarding the trial.Trial registration numberDRKS00014011